| Migraine Disorders
Reyvow vs Zavzpret
Side-by-side clinical, coverage, and cost comparison for migraine disorders.Deep comparison between: Reyvow vs Zavzpret with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZavzpret has a higher rate of injection site reactions vs Reyvow based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zavzpret but not Reyvow, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Reyvow
Zavzpret
At A Glance
Oral
As needed
5-HT1F receptor agonist
Intranasal
As needed
CGRP receptor antagonist
Indications
- Migraine Disorders
- Migraine Disorders
Dosing
Migraine Disorders 50 mg, 100 mg, or 200 mg orally as needed; no more than one dose in 24 hours; wait at least 8 hours between dosing and driving or operating machinery; swallow tablets whole.
Migraine Disorders 10 mg as a single spray in one nostril as needed; maximum 10 mg (one spray) per 24-hour period; safety of treating more than 8 migraines in a 30-day period has not been established.
Contraindications
—
- History of hypersensitivity reaction to zavegepant or any component of ZAVZPRET, including anaphylaxis
Adverse Reactions
Most common (>=2%) dizziness, fatigue, paresthesia, sedation, nausea and/or vomiting, muscle weakness
Serious hypersensitivity reactions including angioedema, rash, and photosensitivity reaction
Most common (>=2%) Taste disorders (dysgeusia, ageusia), nausea, nasal discomfort, vomiting
Serious Hypersensitivity including facial swelling and urticaria (less than 1%)
Postmarketing Hypersensitivity (anaphylaxis), hypertension, Raynaud's phenomenon
Pharmacology
5-HT1F receptor agonist; lasmiditan binds with high affinity to the 5-HT1F receptor and presumably exerts its therapeutic effects in migraine through agonist activity at this receptor, though the precise mechanism is unknown.
Zavegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist; it blocks CGRP receptor signaling implicated in migraine pathophysiology.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Reyvow
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (10/12)
Zavzpret
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (10/12)
UnitedHealthcare
Reyvow
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (5/8) · Qty limit (4/8)
Zavzpret
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Reyvow
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Zavzpret
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Reyvow.
Cost estimate not availablePAF Co-Pay Relief: Migraine
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ReyvowView full Reyvow profile
ZavzpretView full Zavzpret profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.